
NYC and Cambridge-based Empyrean Neuroscience Inc. is a new genetic engineering company developing neuroactive compounds for neuropsychiatric and neurological disorders launching with a $22 million Series A financing.
The company’s CEO is long-time biotech executive Dr. Usman “Oz” Azam, joined by Dr. Fred Grossman as chief medical officer. Azam has previously worked on genetic engineering with Dr. Carl June of the University of Pennsylvania, while Grossman is a psychiatrist that holds expertise in CNS-targeted small molecules development.